CADTH | Evidence Driven
CADTH | Evidence Driven

sofosbuvir / velpatasvir

Details

Generic Name:
sofosbuvir / velpatasvir
Project Status:
Not filed
Therapeutic Area:
Hepatitis C, chronic
Manufacturer:
Gilead Sciences Canada, Inc.
Brand Name:
Epclusa
Project Line:
Reimbursement Review
Project Number:
N/A
Manufacturer Requested Reimbursement Criteria1:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Submission Type:
Non Submission
Indications:
Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients ≥ 12 years of age pediatric patients ≥ 12 years of age and weighing ≥ 30 kg without cirrhosis or with compensated cirrhosis.
Recommendation Type:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : October 16, 2023